[Comment] Non-invasive tests in MASH: clinical practice versus trials
摘要
Non-invasive tests (NITs) are central to clinical decision making in metabolic dysfunction-associated steatotic liver disease, including risk stratification, treatment decisions, referral pathways, and recruitment into clinical trials.1 As pharmacological treatments for metabolic dysfunction-associated steatohepatitis (MASH) become more widely available, the importance of accurately identifying fibrosis stage has grown considerably. In clinical drug trials on MASH, the objective is usually to identify patients with substantial (≥F2) or advanced fibrosis (≥F3) who are most likely to benefit from pharmacological therapy.
摘要 待译
Non-invasive tests (NITs) are central to clinical decision making in metabolic dysfunction-associated steatotic liver disease, including risk stratification, treatment decisions, referral pathways, and recruitment into clinical trials.1 As pharmacological treatments for metabolic dysfunction-associated steatohepatitis (MASH) become more widely available, the importance of accurately identifying fibrosis stage has grown considerably. In clinical drug trials on MASH, the objective is usually to identify patients with substantial (≥F2) or advanced fibrosis (≥F3) who are most likely to benefit from pharmacological therapy.
English
Non-invasive tests (NITs) are central to clinical decision making in metabolic dysfunction-associated steatotic liver disease, including risk stratification, treatment decisions, referral pathways, and recruitment into clinical trials.1 As pharmacological treatments for metabolic dysfunction-associated steatohepatitis (MASH) become more widely available, the importance of accurately identifying fibrosis stage has grown considerably. In clinical drug trials on MASH, the objective is usually to identify patients with substantial (≥F2) or advanced fibrosis (≥F3) who are most likely to benefit from pharmacological therapy.